Easterly Investment Partners LLC Makes New $2.13 Million Investment in UnitedHealth Group Incorporated $UNH

Key Points

• Easterly Investment Partners LLC has made a new investment of $2.13 million in UnitedHealth Group, purchasing 6,837 shares during the second quarter.
• UnitedHealth Group reported quarterly earnings of $4.08 per share, missing analyst expectations, with revenue of $111.62 billion for the quarter.
• The company declared a quarterly dividend of $2.21 per share, which translates to an annualized dividend of $8.84 and a dividend yield of 2.5%.

Easterly Investment Partners LLC bought a new stake in shares of UnitedHealth Group Incorporated (NYSE:UNH - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 6,837 shares of the healthcare conglomerate's stock, valued at approximately $2,133,000.

A number of other institutional investors have also recently modified their holdings of the business. Citizens National Bank Trust Department lifted its stake in UnitedHealth Group by 1.0% in the 1st quarter. Citizens National Bank Trust Department now owns 17,886 shares of the healthcare conglomerate's stock valued at $9,368,000 after buying an additional 170 shares in the last quarter. Caitlin John LLC grew its holdings in shares of UnitedHealth Group by 14.8% in the first quarter. Caitlin John LLC now owns 862 shares of the healthcare conglomerate's stock valued at $451,000 after purchasing an additional 111 shares during the period. Triumph Capital Management acquired a new position in UnitedHealth Group in the 2nd quarter valued at about $1,324,000. Wealth Effects LLC lifted its holdings in UnitedHealth Group by 14.4% in the second quarter. Wealth Effects LLC now owns 4,688 shares of the healthcare conglomerate's stock valued at $1,463,000 after acquiring an additional 591 shares during the last quarter. Finally, Arlington Partners LLC purchased a new stake in UnitedHealth Group in the second quarter valued at $2,229,000. 87.86% of the stock is currently owned by institutional investors and hedge funds.

UnitedHealth Group Stock Performance

Shares of UNH opened at $355.73 on Friday. The company has a 50-day simple moving average of $327.27 and a 200-day simple moving average of $346.01. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 0.73. The company has a market capitalization of $322.17 billion, a PE ratio of 15.41, a P/E/G ratio of 2.33 and a beta of 0.47. UnitedHealth Group Incorporated has a 52-week low of $234.60 and a 52-week high of $630.73.

UnitedHealth Group (NYSE:UNH - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The healthcare conglomerate reported $4.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.45 by ($0.37). The company had revenue of $111.62 billion during the quarter, compared to analysts' expectations of $111.75 billion. UnitedHealth Group had a net margin of 5.04% and a return on equity of 23.32%. The business's revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.80 EPS. UnitedHealth Group has set its FY 2025 guidance at 16.000- EPS. Equities research analysts predict that UnitedHealth Group Incorporated will post 29.54 earnings per share for the current fiscal year.

UnitedHealth Group Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 23rd. Shareholders of record on Monday, September 15th were paid a dividend of $2.21 per share. This represents a $8.84 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend was Monday, September 15th. UnitedHealth Group's dividend payout ratio (DPR) is currently 38.30%.

Analyst Ratings Changes

UNH has been the subject of several research analyst reports. Piper Sandler lowered their price target on UnitedHealth Group from $353.00 to $317.00 and set an "overweight" rating for the company in a research report on Wednesday, July 30th. Weiss Ratings reiterated a "sell (d+)" rating on shares of UnitedHealth Group in a report on Wednesday, October 8th. Sanford C. Bernstein boosted their price target on shares of UnitedHealth Group from $379.00 to $433.00 and gave the stock an "outperform" rating in a report on Wednesday, October 8th. Baird R W cut shares of UnitedHealth Group from a "hold" rating to a "strong sell" rating in a report on Thursday, July 31st. Finally, JPMorgan Chase & Co. upped their target price on shares of UnitedHealth Group from $310.00 to $425.00 and gave the company an "overweight" rating in a report on Thursday, October 9th. Seventeen analysts have rated the stock with a Buy rating, seven have given a Hold rating and four have issued a Sell rating to the company's stock. According to MarketBeat.com, UnitedHealth Group presently has a consensus rating of "Hold" and a consensus price target of $384.09.

UnitedHealth Group Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.